secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-05-15T20:27:48+00:00
Accession:  0001178913-26-002739
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Silexion Therapeutics enters inducement agreement for exercise of ~2M warrants at $0.50, raising ~$1M
--------------------------------------------------------------------------------

- Holders of 1,995,092 existing warrants (Series A/B at $4.00, Prior Inducement at $11.32) agree to exercise at reduced price of $0.50 per share.
- Gross proceeds of approximately $1.0 million expected from the warrant exercise, with H.C. Wainwright as placement agent earning 7% cash fee.
- Company will issue new Series C (2,045,000) and Series D (1,945,184) warrants exercisable at $0.50, totaling 3,990,184 new warrant shares.
- Closing expected on or about May 18, 2026, with net proceeds used for general corporate purposes.
- Placement agent also receives warrants to purchase up to 139,656 ordinary shares at $0.625 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002739/0001178913-26-002739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002739/zk2635351.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-002739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer